Previous 10 | Next 10 |
Gainers: Reata Pharmaceuticals (RETA) +20%, LifeMD (LFMD) +13%, Eloxx Pharmaceuticals (ELOX) +10%, Cerecor (CERC) +10%, Biofrontera (BFRA) +7%.Losers: Onconova Therapeutics (ONTX) -23%, Iovance Biotherapeutics (IOVA) -18%,&...
Gainers: [[VRNA]] +31.8%. [[PDD]] +6.1%. [[SHYF]] +4.6%. [[OCX]] +3.9%. [[VERI]] +3.9%.Losers: [[IOVA]] -11.1%. [[PRPL]] -4.0%. [[PRVB]] -3.4%. [[OZON]] -3.3%. [[ACCD]] -3.0%. For further details see: VRNA, PDD, IOVA and PRVB among after-hours movers
Iovance Biotherapeutics (IOVA) announces receipt of regulatory feedback from the U.S. FDA regarding its potency assays for melanoma treatment lifileucel, and provides a regulatory timeline update.Shares down nearly 13% post-market.The company said that its biologics licens...
SAN CARLOS, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regardi...
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up C-144-01 Study Contributes to Advancement in TIL Therapy Using Centrally Standardized Manufacturing, Allowing for Broadened Patient Access SAN CARLOS, Calif., May 12, 2021 (GLOBE NEWSWIRE)...
Iovance Biotherapeutics, Inc. (IOVA) Q1 2021 Earnings Conference Call May 6, 2021 04:30 PM ET Company Participants Maria Fardis - Chief Executive Officer & President Friedrich Finckenstein - Chief Medical Officer Jean Marc Bellemin - Chief Financial Officer Sara Pellegrino - Vice Presiden...
SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported first quarter...
Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study Initial Data for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor Naïve Advanced Melanoma Cohort 1A in IOV-COM-202 Clinical Study SAN CARLOS, Calif., April 28, 2021 (GLOBE NEWS...
SAN CARLOS, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6, 2021. Management will host a conf...
Buying stocks in a bear market necessitates courage, as you need to overcome your fear. Conquering your fear to purchase during a down cycle usually leads to outsized returns. Iovance Biotherapeutics is a fundamentally robust stock that is experiencing a decline. That makes it an idea...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...